Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2595MR)

This product GTTS-WQ2595MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2595MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13041MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ5519MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ4965MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ6855MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ4187MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ1833MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ10705MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ4952MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW